The review says GLP-1 drugs cut albuminuria and slow kidney decline, with semaglutide backed by the strongest data in type 2 diabetes with chronic kidney disease.
Recap by typeshit. Full story at News-Medical.Net.
6:25
Dr Almerie compares Lilly's experimental retatrutide with Mounjaro and talks through the case for switching versus holding off until it's approved.
He points to GLP-1 receptors in the hypothalamus, saying the medication boosts fullness signals and slows the stomach, which changes how hunger feels.
10:08
Weight loss doctor Bazgha Khalid goes through what the published trials actually show for Zepbound against Lilly's newer retatrutide.
Patients who took a GLP-1 receptor agonist before surgery did not lose more weight at one year, JAMA Surgery reports. The full study has the details.
Shields Health Solutions argues dropout is a support gap, citing its pharmacist-led program where only 19.7% quit at one year.
Meta-analyses show four to six times more retained stomach contents in users, and guidance is moving from blanket pauses toward case-by-case plans.
Loading…